


Abstract

5 The present invention is directed to carbocyclic hydrazino compounds that
function as inhibitors of copper-containing amine oxidases commonly known as
semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO
known as Vascular Adhesion Protein-1 (VAP-1). These SSAO inhibitors have
therapeutic utility as drugs to treat conditions and diseases including, but not
10 limited to, a number of inflammatory conditions and diseases (in particular chronic
inflammatory conditions such as chronic arthritis, inflammatory bowel diseases,
and chronic skin dermatoses), diseases related to carbohydrate metabolism and to
aberrations in adipocyte differentiation or function and smooth muscle cell
function, and vascular diseases. The novel compounds have the general formula:

15



or a pharmaceutically acceptable solvate, hydrate, or salt thereof, wherein R¹ to R¹¹ are as defined herein.